Valuation: Evotec

Market Cap 490M 557M 461M 421M 787M 53.42B 793M 5.54B 2.15B 27.19B 2.09B 2.04B 88.48B P/E 2026 *
-2.16x
P/E 2027 * -6.4x
Enterprise Value 632M 719M 596M 544M 1.02B 69.01B 1.03B 7.15B 2.77B 35.12B 2.7B 2.64B 114B EV / Sales 2026 *
1.05x
EV / Sales 2027 * 0.9x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO - 2026-04-30
Chief Operating Officer - 2026-04-30
Director TitleAgeSince
Director/Board Member 58 2019-06-18
Director/Board Member 64 2021-05-31
Director/Board Member 59 2024-06-09
Change 5-day change 1-year change 3-year change Capi.($)
-78.72%0.00% - - 557M
-1.04%+3.34%+8.84%+30.48% 48.01B
+2.67%+2.07%+51.74%+38.37% 45.27B
-1.38%+1.84%+9.13%+88.88% 40.93B
+4.78%+1.48%+359.03%+566.20% 42.84B
-0.62%-1.61%+5.30%+46.02% 29.6B
+0.56%+0.88%+24.79%+155.71% 17.32B
-0.59%+1.07%+26.61%+41.14% 15.34B
+3.39%-3.49% - - 15.15B
+7.38%+2.34%+3.80% - 14.84B
Average -7.61%+1.02%+61.16%+138.12% 29.92B
Weighted average by Cap. -0.08%+1.56%+77.01%+149.53%

Financials

2026 *2027 *
Net sales 601M 683M 566M 517M 966M 65.58B 974M 6.8B 2.63B 33.37B 2.56B 2.51B 109B 724M 823M 683M 623M 1.16B 79.02B 1.17B 8.19B 3.17B 40.22B 3.09B 3.02B 131B
Net income -222M -252M -209M -191M -357M -24.23B -360M -2.51B -973M -12.33B -948M -927M -40.12B -48.25M -54.85M -45.48M -41.5M -77.61M -5.27B -78.21M -546M -212M -2.68B -206M -201M -8.72B
Net Debt 143M 162M 135M 123M 230M 15.59B 232M 1.62B 626M 7.93B 610M 597M 25.82B 162M 184M 153M 139M 261M 17.7B 263M 1.83B 711M 9.01B 692M 677M 29.31B
Logo Evotec
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
2.754EUR
Average target price
4.586EUR
Spread / Average Target
+66.51%

Quarterly revenue - Rate of surprise